Harry Miao
About Harry Miao
Harry Miao serves as the Vice President of Clinical Development at Kite Pharma, where he has worked since 2021. He has held various leadership roles in clinical development across multiple pharmaceutical companies, including Incyte, PTC Therapeutics, Sanofi, Epizyme, Takeda Oncology, and ImClone Systems.
Work at Kite Pharma
Harry Miao serves as the Vice President of Clinical Development at Kite Pharma, a position he has held since 2021. In this role, he is responsible for overseeing clinical development strategies and initiatives within the organization. Kite Pharma specializes in innovative cancer therapies, particularly in the field of cell therapy. Miao's leadership contributes to the advancement of clinical programs aimed at improving patient outcomes.
Previous Experience in Clinical Development
Before joining Kite Pharma, Harry Miao held several significant roles in clinical development across various organizations. He worked at Incyte as Executive Director from 2014 to 2016. Prior to that, he served as Director of Clinical Development at PTC Therapeutics, Inc. from 2007 to 2010. Miao also held the position of Director at Sanofi from 2010 to 2014, and later worked as Executive Director at Epizyme from 2016 to 2018. His experience spans over two decades in the biopharmaceutical industry.
Experience at Takeda Oncology
Harry Miao worked at Takeda Oncology as Executive Medical Director from 2018 to 2021. In this role, he was involved in the development and execution of clinical strategies for oncology products. His tenure at Takeda contributed to the company's efforts in advancing cancer treatment options and enhancing clinical trial designs.
Career at ImClone Systems
Miao began his career in clinical development at ImClone Systems, a subsidiary of Eli Lilly and Company, where he served as Associate Director from 2000 to 2007. During his time at ImClone, he contributed to the development of targeted therapies in oncology, gaining valuable experience that shaped his future roles in the industry.